English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

In 2008, the U.S. Food and Drug Administration requested that all new type 2 anti-diabetic drugs, including long-acting insulin analogues, need to be rigorously examined to preclude undesirable cardiovascular risks. The Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial is the first trial to provide conclusive evidence of the cardiovascular safety of insulin glargine. A total of 12,537 people with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes were randomized to receive insulin glargine or standard care. This article is protected by copyright. All rights reserved.

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?